SCHEMBL31224327

SCHEMBL31224327

CNC(=O)c1cc(Cl)nc(C)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BAZ2B Q9UIF8 1/20 0.47
BRD4 O60885 5/20 0.42
DPP4 P27487 1/20 0.41
DPP8 Q6V1X1 1/20 0.41
PDK2 Q15119 1/20 0.41
RAB9A P51151 3/20 0.40
GAA P10253 1/20 0.40
SCN10A Q9Y5Y9 2/20 0.39
SCN1A P35498 1/20 0.38
KCNH2 Q12809 1/20 0.38
SCN5A Q14524 1/20 0.38
SCN9A Q15858 1/20 0.38
SCN2A Q99250 1/20 0.38
SCN3A Q9NY46 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
NPC1 O15118 2/20 0.38
CNR1 P21554 1/20 0.37
POLB P06746 1/20 0.37
S1PR2 O95136 1/20 0.37
NFKB1 P19838 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11925521 0.79 BAZ2B (0.44) BAZ2BBRD4DPP4DPP8RAB9A
SCHEMBL14609864 0.79 BAZ2B (0.44) BAZ2BBRD4DPP4DPP8PDK2
SCHEMBL30528409 0.79 KMO (0.39) RAB9AGAANPC1POLBS1PR2
SCHEMBL9196203 0.79 KMO (0.54) RAB9AL3MBTL1NPC1S1PR2SMN1; SMN2
SCHEMBL985142 0.79 KMO (0.39) RAB9AGAANPC1POLBS1PR2
SCHEMBL3641920 0.78 KDM4E (0.44) RAB9ANPC1SMN1; SMN2
Hydrochloric Acid SCHEMBL2192452 0.77 KMO (0.53) RAB9AL3MBTL1NPC1S1PR2SMN1; SMN2
SCHEMBL24150163 0.76 SCN10A (0.44) BAZ2BBRD4DPP4DPP8RAB9A
SCHEMBL31312497 0.76 BRD4 (0.41) BAZ2BBRD4DPP4DPP8RAB9A
SCHEMBL29331761 0.76 BRD4 (0.41) BAZ2BBRD4DPP4DPP8RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024259171-A9 KEAP1 INHIBITORS AND USES THEREOF VIVIDION THERAPEUTICS, INC. (US) 2025-01-23 WO disclosed
US-20250011291-A1 KEAP1 INHIBITORS AND USES THEREOF VIVIDION THERAPEUTICS, INC. 2025-01-09 US disclosed
WO-2024259171-A2 KEAP1 INHIBITORS AND USES THEREOF VIVIDION THERAPEUTICS, INC. (US) 2024-12-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250011291-A1 KEAP1 INHIBITORS AND USES THEREOF KEAP1, NFE2L2, NQO1 BAZ2B 180/4885BRD4 968/4885DPP4 4062/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.